SJ-3366 Sam Jin Pharmaceutical.

Abstract

Sam Jin is investigating SJ-3366, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the potential treatment of HIV infection [302450]. As well as acting as an NNRTI, SJ-3366 also interferes with HIV-1 entry via an intermediate target formed after virus-cell attachment [341146], [363900]. As of June 1998, Sam Jin had been awarded a patent for SJ-3366 in South Africa, with applications pending in 22 other countries [302450].

• Authors: Masanori Baba
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 8 Pg. 1146-8 (Aug 2002) ISSN: 1472-4472 [Print] England
• PMID: 12211405 (Publication Type: Journal Article, Review)

Chemical References

• Pyrimidinones
• Reverse Transcriptase Inhibitors
• SJ3366
• HIV Reverse Transcriptase

Topics

• HIV Infections (drug therapy)
• HIV Reverse Transcriptase (metabolism)
• Humans
• Patents as Topic
• Pyrimidinones (pharmacology, therapeutic use)
• Reverse Transcriptase Inhibitors (pharmacology, therapeutic use)